Led by Jeffrey Towbin, MD, Le Bonheur’s Pediatric Cardiomyopathy program draws patients from across the country for the diagnosis and management all types of cardiomyopathy in children, including:
- Dilated cardiomyopathy, a condition in which the heart’s left ventricle becomes enlarged, and the heart muscle thins, leaving the heart unable to pump blood efficiently throughout the body
- Hypertrophic cardiomyopathy, a condition in which the heart muscle thickens (usually the left ventricle), making it difficult for blood to flow through the heart
- Restrictive cardiomyopathy, a condition in which the heart muscle becomes stiff and rigid, limiting blood flow in the heart
- Left ventricular non-compaction, a condition that results from a failure of the compaction process (during the heart's development) that turns the heart tissue from sponge-like to solid
- Arrhythmogenic right ventricular dysplasia, a condition that causes tissue in the right ventricle to die and become replaced with scar tissue. This condition causes irregular heartbeats.
We provide a range of treatment options and work to provide the best individualized plan of care for your child. Treatment options include:
- Drug therapy
- Catheter-based procedures
- Implantation of devices, including Mechanical Circulatory Support (MCS) and Ventricular Assist Device (VAD)
- Cardiac ECMO (extracorporeal membrane oxygenation)
- Cardiovascular surgery, including transplant
We also have sources for genetic screening and testing to determine a patient’s risk of cardiomyopathy.
Cardiomyopathy and Muscular Dystrophy
Le Bonheur Children’s is home to one of the region’s only Muscular Dystrophy Association (MDA) Clinics. Some children with muscular dystrophy develop dilated cardiomyopathy and are at risk of heart failure. In partnership with our MDA Clinic, we offer a full-range for treatment options to diagnose and manage cardiac disease in children with neuromuscular disorders.
Cardiomyopathy and Cancer
We partner with St. Jude Children’s Research Hospital to care for children with cancer-related heart failure, including chemotherapy-induced cardiotoxicity.